-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Kiniksa Pharmaceuticals International, plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
- Kiniksa Pharmaceuticals International, plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$12.6M, a 9.12% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2024 was -$9.11M, a 37.5% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $14M, a 92.3% decline from 2022.
- Kiniksa Pharmaceuticals International, plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $183M.
- Kiniksa Pharmaceuticals International, plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$158M, a 2.16% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)